PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today announced the availability of an independent research report that was issued yesterday with a “Strong Buy” recommendation and a 12- to 18-month price target of $4.75. The report is authored by Stephen M. Dunn, senior managing director/research, and William D. Dawson, senior vice president/research, for LifeTech Capital, a division of Aurora Capital LLC. It can be found online at: www.lifetechcapital.com.
